European Union (EU) regulators have delayed a decision to give approval for Novavax’s (NVAX.O) variant-tailored COVID-19 vaccine, the Financial Times said on Sunday.
The European Medicines Agency (EMA), which was due to approve the updated vaccine last Friday has requested more information from the company, the FT report added.
Comments closedThe last remaining manufacturer to offer an alternative to mRNA COVID-19 vaccines in Canada is hopeful it will meet the government’s 2024 deadline to make the shots domestically.
Comments closedThe last manufacturer to offer an alternative to COVID-19 mRNA vaccines in Canada hopes to meet the government’s 2024 deadline for domestic dose production.
Novavax, based in Maryland, USA, held a press conference on Wednesday to tout the safety and efficacy of its new vaccine, which targets newer strains of COVID-19.
Comments closedThe Food and Drug Administration announced Tuesday it had authorized Novavax’s updated COVID-19 vaccine, adding a third option for Americans ages 12 and older looking for a new shot this fall and winter.
Comments closedCovid-19 vaccines that have been tweaked to teach the body how to fend off the current crop of circulating variants are now expected to land in drugstores and clinics in mid-September, CDC and FDA officials said.
Comments closed